Statistical analysis
treatment-naive advanced ALK-positive NSCLC
The sample size was calculated with PASS 16.0. The estimated median PFS of participants with treatment-naive advanced ALK-positive NSCLC administered crizotinib monotherapy was 11 months; the estimated PFS was 5.67 months longer in participants administered envonalkib compared with crizotinib, indicating an HR of 0.66. The randomization ratio of the two groups was 1:1; The ITT population included all randomized participants and was used in the efficacy analysis. The SS included all participants administered with the study drug at least once and whose safety assessments were available and was used for safety analysis.Continuous data were presented as mean ± standard deviation or median and interquartile range (IQR) and compared between the two groups by independent samples 